Does Cigna Cover Prolia? A Complete Coverage Guide

What Is Prolia and Why Does Coverage Get Complicated?

Prolia is a RANK ligand inhibitor that slows bone breakdown by blocking the protein that activates osteoclasts. The FDA approved it in June 2010 for postmenopausal women at high fracture risk and later for men with osteoporosis, patients receiving androgen-deprivation therapy for prostate cancer, and patients on aromatase inhibitors for breast cancer [1]. Each dose is 60 mg delivered as a subcutaneous injection every six months, typically given in a physician's office.

Coverage gets complicated because Prolia sits at the intersection of two separate benefit streams. When a provider purchases the drug and administers it in-office, it usually bills under the medical benefit using the HCPCS code J0897. When a specialty pharmacy dispenses it for home administration, the pharmacy benefit applies instead. Cigna adjudicates those two pathways under different formulary rules, different cost-sharing tiers, and different prior authorization (PA) criteria. A member with a $30 specialist copay could face a very different out-of-pocket bill than a member whose plan assigns Prolia to Tier 4 or 5 on the pharmacy formulary.

The FREEDOM trial (N=7,808), the key Phase 3 study supporting FDA approval, showed denosumab reduced new vertebral fractures by 68% over 36 months (relative risk 0.32 to 95% CI 0.26, 0.41, P<0.001) compared with placebo [2]. That evidence base is strong enough that most payers including Cigna accept the clinical case for coverage; the friction is administrative, not scientific.

Cigna's General Coverage Policy for Prolia

Cigna maintains a Medical Coverage Policy document specifically for receptor activator of nuclear factor kappa-B ligand (RANK-L) inhibitors. The policy is updated periodically and covers both Prolia and Xgeva (the higher-dose denosumab used in oncology). For the osteoporosis indication, Cigna's published criteria generally require all of the following to be met before approving a PA request:

1. A diagnosis of osteoporosis confirmed by dual-energy X-ray absorptiometry (DXA) showing a T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip.
2. Documentation that the patient has experienced an osteoporotic fracture, or that the prescriber has determined fracture risk is high based on FRAX score or clinical presentation.
3. Failure, intolerance, or a documented contraindication to at least one oral bisphosphonate. Alendronate (Fosamax) and risedronate (Actonel) are the agents Cigna most commonly names as required first-line therapies.
4. A prescription from a physician (typically an endocrinologist, rheumatologist, or gynecologist, though primary care providers can also prescribe).

The National Osteoporosis Foundation, now part of the American Bone Health organization, and the Endocrine Society both recognize denosumab as a second-line agent after bisphosphonate failure or intolerance, which aligns with Cigna's step-therapy requirement [3]. The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines specifically state that denosumab is appropriate for patients with high or very high fracture risk, particularly those who cannot tolerate oral bisphosphonates [4].

The table below maps the most common Cigna plan types to their typical Prolia adjudication pathway. Editors: insert the original decision framework diagram here showing plan type, benefit stream, PA criteria checklist, and appeal pathway.

How the Prior Authorization Process Works Step by Step

Prior authorization for Prolia under Cigna is not optional. It runs through Cigna's specialty drug PA unit, and the clock starts the moment the prescribing office submits the request. Here is how the process typically unfolds.

Step 1: The prescriber submits a PA request. The office completes Cigna's PA form (available through Cigna's provider portal at cigna.com) or uses the EviCore healthcare platform, which Cigna contracts with to manage specialty drug reviews. The submission needs to include the patient's DXA report with T-scores, a fracture history if applicable, a FRAX calculation if relevant, and documentation of the bisphosphonate trial.

Step 2: Cigna or EviCore reviews the request. The standard review window under most state regulations and Cigna's own policy is up to 3 business days for standard PA and 1 business day for urgent PA. If information is incomplete, the reviewer issues a request for additional clinical information, which pauses the clock.

Step 3: Approval or denial is issued. An approval typically covers two injections per 12-month period (one every six months). A denial will cite the specific criterion not met, and the denial letter must include instructions for appeal.

Step 4: Appeal or peer-to-peer review. A prescribing physician can request a peer-to-peer call with the Cigna or EviCore medical director reviewing the case. Peer-to-peer calls resolve a substantial portion of initial denials, particularly when the prescriber can articulate why bisphosphonate therapy is contraindicated (for example, severe GERD, renal insufficiency with an eGFR <35 mL/min/1.73m², or a history of osteonecrosis risk). A formal first-level appeal can be filed within 180 days of the denial.

Step 5: External review. If the internal appeal is denied, most state laws and the ACA require insurers to offer independent external review. Cigna must comply with state external review rules in the 50 states where it operates.

Medicare Advantage vs. Commercial Cigna Plans

The coverage pathway differs meaningfully depending on whether you hold a Cigna commercial policy or a Cigna Medicare Advantage (MA) plan.

Commercial plans follow the formulary and PA criteria described above. Employer-sponsored plans may have negotiated different formulary tiers, so a Cigna plan offered through a large employer could have more favorable Prolia coverage than an individual market plan.

Cigna Medicare Advantage plans must, by federal law, cover any Part B drug that traditional Medicare covers. Prolia administered in a physician's office qualifies as a Part B drug under HCPCS J0897. Under traditional Medicare Part B, Prolia is reimbursed at the average sales price (ASP) plus 6%, and Cigna MA plans use the same reimbursement logic but apply their own cost-sharing rules. Beneficiaries in the catastrophic phase of drug coverage may see dramatically lower out-of-pocket costs starting in 2025 under the Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D drugs (though Part B drugs like Prolia are governed separately) [5].

Cigna+Oscar plans, sold on the ACA marketplaces, tend to tier Prolia as a specialty drug (Tier 4 or 5) with coinsurance of 30 to 50% after deductible. Members on these plans should ask their prescriber to submit under the medical benefit (in-office injection via J0897) rather than the pharmacy benefit to potentially reduce cost exposure.

How Much Will You Pay Out of Pocket?

The average wholesale price for Prolia 60 mg is approximately $1,900, $2,100 per injection as of late 2024, meaning the annual drug cost runs roughly $3,800, $4,200 before any plan discounts or rebates [6]. What you actually pay depends heavily on benefit design.

Under the medical benefit (in-office injection), Prolia is typically subject to your specialist office-visit copay or, if your plan uses coinsurance after a deductible, to the coinsurance percentage applied to the allowed amount. Plans that have negotiated a lower contracted rate may reimburse providers at significantly below AWP.

Under the pharmacy benefit, specialty drug tiers commonly carry coinsurance of 25 to 40% with no cap until the out-of-pocket maximum is reached. On a $3,800 annual drug cost with 30% coinsurance and a $3,000 deductible, you could theoretically owe the full deductible before coinsurance kicks in, then 30% of the remaining balance.

Amgen offers a co-pay assistance program called the Prolia SupportPlus program for commercially insured patients (not Medicare). Eligible patients may pay as little as $0 per injection through this program, subject to income and eligibility criteria. Patients on Medicare are not eligible for manufacturer co-pay cards under federal anti-kickback rules, but they may qualify for the Amgen Safety Net Foundation for low-income patients [7].

What Happens If Cigna Denies Your Prolia Claim?

Denial is not the end of the road. The most effective first response is a physician-initiated peer-to-peer review call with the reviewing Cigna or EviCore medical director. Published data on specialty drug PA appeals in rheumatology and endocrinology suggest that peer-to-peer review overturns initial denials in approximately 40 to 60% of cases when the prescriber provides additional clinical context [8].

If Cigna denies coverage on the grounds that an oral bisphosphonate has not been tried, the prescriber must document a clinical reason to bypass step therapy. Acceptable bypass criteria that appear in most state laws and Cigna's own exception policies include:

• A documented adverse reaction to bisphosphonates such as esophageal irritation or atypical femur fracture risk.
• Renal impairment. Alendronate is contraindicated when creatinine clearance is <35 mL/min, and risedronate carries similar renal precautions. For a patient with stage 3b or 4 chronic kidney disease, denosumab may be the only viable bone-remodeling agent.
• Patient history of Barrett's esophagus or active upper GI disease.
• Demonstrated non-response. A patient who fractured on bisphosphonate therapy has compelling clinical grounds for escalation.

The American Society for Bone and Mineral Research published a position statement noting that patients who sustain a fracture while on bisphosphonate therapy should be evaluated promptly for alternate agents, including denosumab [9]. That statement can serve as supporting literature in an appeal letter.

Denosumab Biosimilars and What They Mean for Cigna Formularies

The FDA approved two denosumab biosimilars in May 2024: Jubbonti (denosumab-bbdz) by Sandoz and Wyost (denosumab-bbdz) by Sandoz, followed by additional biosimilar applications under review [10]. Biosimilars are typically priced 15 to 30% below the reference brand, and insurers including Cigna may move to prefer biosimilars on formulary as they gain market share.

If Cigna designates a denosumab biosimilar as the preferred product on your plan's formulary, your prescriber may be asked to prescribe the biosimilar instead of branded Prolia. The FDA has determined that FDA-approved biosimilars are interchangeable with the reference product for the approved indications, meaning a pharmacist could in some states substitute the biosimilar without additional prescriber authorization. Patients who have already started Prolia and are mid-sequence (given that abrupt discontinuation carries a rebound fracture risk) should discuss continuity of therapy with their prescriber before any formulary-driven switch [11].

A 2023 analysis in the Journal of Bone and Mineral Research noted that discontinuation of denosumab without transitioning to a bisphosphonate is associated with rapid bone mineral density loss and an increased risk of vertebral fracture within 12 months [12]. That risk applies regardless of whether the discontinuation is patient-initiated or formulary-driven. Prescribers should document this clinical concern in the patient record and in any formulary exception requests.

Tips for Getting Prolia Covered by Cigna the First Time

These steps reduce the probability of a PA denial or delay.

Confirm the benefit pathway before prescribing. Call Cigna provider services (1-800-88-Cigna for providers) or use the Cigna provider portal to determine whether Prolia will process under J0897 (medical benefit) or through specialty pharmacy. Choose the pathway with the lower patient cost-share and the clearer PA criteria.

Build a complete PA packet upfront. Include the DXA report with T-scores, the FRAX 10-year fracture probability calculation, a narrative note documenting bisphosphonate history or contraindication, and any relevant lab values (calcium, vitamin D 25-OH level, creatinine, eGFR). Incomplete submissions are the single most common reason for processing delays.

Reference guideline language directly. Cigna's own medical coverage policy cites the AACE clinical practice guidelines and the Endocrine Society guidelines. Quoting the AACE 2020 guideline statement that "denosumab is recommended for patients at high or very high fracture risk, especially those intolerant of oral bisphosphonates" gives the reviewer a familiar authority to anchor approval [4].

Document the rebound fracture risk for continuity. If the patient is already on Prolia and coverage is being newly established (for example, following a job change), note in the PA request that discontinuation without bisphosphonate bridging carries a clinically documented fracture risk. This framing often accelerates approval for continuity-of-care requests.

Set a PA renewal calendar. Cigna PA approvals for Prolia typically cover 12 months (two injections). Renewals require new documentation. Missing the renewal deadline can result in a lapse in coverage and a gap in therapy. Schedule the renewal submission 60 days before the current PA expires.

Cigna Coverage for Prolia in Men and Oncology Patients

Prolia holds FDA approval for three additional indications beyond postmenopausal osteoporosis: osteoporosis in men at high fracture risk, bone loss in men receiving androgen-deprivation therapy (ADT) for non-metastatic prostate cancer, and bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer [1]. Cigna's coverage policy addresses these indications separately.

For men on ADT, the clinical evidence is clear. A Phase 3 trial (N=1,468) found that denosumab increased lumbar spine bone mineral density by 5.6% versus a 1.0% decrease with placebo at 24 months (P<0.001) [13]. Cigna generally requires documentation of ADT use, a baseline DXA, and T-score criteria similar to those used for postmenopausal osteoporosis.

For aromatase inhibitor-associated bone loss, Cigna's criteria mirror those for postmenopausal osteoporosis but typically require a documented T-score below -2.0 given the accelerated bone loss associated with estrogen suppression from agents such as anastrozole, letrozole, and exemestane.

Physicians treating cancer patients should note that the higher-dose denosumab product (Xgeva, 120 mg every four weeks) is a separate drug with separate coverage criteria and a separate PA pathway. Prolia and Xgeva are not interchangeable.

When Cigna Won't Cover Prolia: Alternatives to Consider

If coverage is exhausted after appeals and external review, several clinical and financial alternatives exist.

Zoledronic acid (Reclast) 5 mg IV once yearly is a bisphosphonate with strong efficacy data. The HORIZON Key Fracture Trial (N=7,765) showed a 70% reduction in morphometric vertebral fractures over 36 months (relative risk 0.30 to 95% CI 0.24, 0.38, P<0.001) [14]. Zoledronic acid is covered under most medical benefits as an infusion and carries a much lower AWP than denosumab.

Romosozumab (Evenity) 210 mg SC monthly for 12 months is an anabolic agent approved for postmenopausal women with osteoporosis at high fracture risk. The ARCH trial showed romosozumab followed by alendronate reduced new vertebral fractures by 48% compared with alendronate alone [15]. Cigna covers romosozumab with similar PA criteria but adds a cardiovascular risk warning requirement given the ARCH trial's finding of slightly increased major adverse cardiovascular events in the romosozumab arm.

Teriparatide (Forteo) and abaloparatide (Tymlos) are anabolic PTH-pathway agents. Both require PA and step-therapy documentation. They are generally reserved for patients with very high fracture risk or multiple vertebral fractures given their higher costs and daily injection schedules.

For patients who cannot afford any of these options, the Partnership for Prescription Assistance (now NeedyMeds at needymeds.org) and state pharmaceutical assistance programs offer means-tested support, though these fall outside the Cigna coverage framework.

A Note on the Cigna + Express Scripts Integration

Cigna completed its acquisition of Express Scripts in 2018, and many Cigna pharmacy benefits are now administered through Express Scripts (ESI). For Prolia processed under the pharmacy benefit, the specialty pharmacy used is typically Accredo, which is Express Scripts' specialty pharmacy arm. Members should confirm whether their plan requires Prolia to be dispensed through Accredo or another Cigna-preferred specialty pharmacy, as using an out-of-network specialty pharmacy can result in claim denial regardless of PA status.

Prescribers should send electronic PA requests and prescriptions through the ESI prescriber portal or through electronic prior authorization (ePA) platforms like CoverMyMeds to minimize processing delays. Phone-based PA requests to Accredo's PA line (1-800-803-2523 as of 2024) remain an option for urgent cases.